Background: Frontotemporal dementia (FTD) is a heterogeneous neurodegenerative disorder associated with frontal and temporal atrophy. Subcortical involvement has been described as well, with early thalamic atrophy most commonly associated with the C9orf72 expansion.
Introduction
Frontotemporal dementia (FTD) is a clinically, pathologically and genetically heterogeneous neurodegenerative disorder, associated with frontal and temporal atrophy. Subcortical involvement has been found in a number of studies [ with TDP-43 pathology [Rohrer et al., 2010b] , although a recent voxel-based morphometry study found thalamic involvement in both TDP-43 and tau-associated FTD cases [Harper et al, 2017 ]. Neuropathologically, one study described a thalamic volume loss of 28-37% in FTD [Mann and South, 1993] , although a more recent study only found significant thalamic atrophy in C9orf72 cases, and not in sporadic cases with TDP-43 pathology [Yang et al., 2017] . Despite these studies, it remains unclear whether and to what extent the thalamus is impaired in the other genetic forms of FTD, or across the different clinical and pathological diagnoses.
The thalamus is an important hub within many networks in the brain as it integrates somatosensory, motor, visual and auditory information through reciprocal connections with the cortex. The thalamus is composed of 50-60 different subnuclei and each nucleus has a distinct pattern of cortical and subcortical connectivity [Herrero et al., 2002] . The dorsomedial and anteroventral nuclei are part of the dorsolateral prefrontal circuit, related to executive functions and motor programming, and also part of the lateral orbitofrontal circuit, related to personality and mood regulation. Being such a relevant brain structure interconnected to virtually all brain regions, the thalamus is likely to be a key structure involved in FTD. We therefore aimed to investigate thalamic involvement in a large cohort of
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patients across the whole FTD spectrum, including those with genetic and pathological confirmation.
Methods
We analysis. We also investigated asymmetry by calculating an Asymmetry Index (AI), defined as the absolute difference between the left and right thalamic volumes in relation to the total bilateral volume: |(Left -Right)|/(Left + Right).
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Results
Sociodemographic and clinical data are reported in Investigating the control group, there was a weak but significant negative correlation of thalamic volume with age (Spearman's rho: -0.444, p-value <0.0005).
Overall, the total FTD group had significantly smaller thalami than controls (10% and 6% difference in the left and right volume respectively, p<0.0005, ANCOVA).
All clinical subtypes showed significantly smaller thalami than controls (p<0.0005, ANCOVA), with the FTD-MND group having the smallest (17 and 13%, left and right), followed by bvFTD (10 and 8%), PNFA (10 and 6%), PPA-NOS (12 and 2%) and lastly SD (9 and 0.1%). Comparing disease groups, FTD-MND showed significantly smaller volumes when compared to all the other clinical subgroups, except for PPA-NOS; bvFTD showed significantly smaller thalami than PNFA, PPA-NOS and SD; PNFA showed a smaller right thalamus than PPA-NOS and bilaterally smaller volumes than SD; while PPA-NOS showed bilaterally smaller thalami than SD ( Table 2 ).
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Stratifying by genetics, C9orf72 group had the smallest thalami (left: 15 and right:
13% difference from controls, p<0.0005). However, the thalami were also smaller than controls in the other genetic groups: GRN (13 and 9%, p<0.0005) and MAPT (12 and 7%, p<0.0005) groups. There were no significant differences between the disease groups. Note that excluding the genetic cases and analyzing the sporadic cases alone (n=274) also showed a similar pattern of smaller thalami than controls (4% difference on the left, 9% on the right, and 7% in total, p<0.0005 ANCOVA -Supplementary Table 2 for more detailed analysis).
In the pathological groups, the TDP-43opathies had a 14% (left) and 8% (right) difference from controls (p<0.0005), and tauopathies 12 and 6% (p<0.0005), while the FUSopathies showed the smallest difference from controls (1 and 3%, p<0.0005).
Comparing disease groups, only the tau group showed a smaller (left) thalamic volume than the FUS group (p=0.011) ( Table 2) .
Among the clinical groups, the ROC analysis showed the highest diagnostic accuracy between FTD-MND and SD (right thalamus, AUC=0.921, p<0.0005) ( Table   2 ). In the genetic groups the ROC analysis showed a poor ability to separate C9orf72 from MAPT, with the highest AUC value for the right thalamus (AUC=0.679, p=0.034) and from GRN cases (AUC=0.644, p=0.133 for the sum of right and left) ( Table 2) . For the pathological groups, the highest accuracy was when differentiating between TDP-43 and tau for the left thalamus volume (AUC=0.869, p-value=0.032).
When investigating the asymmetry of the thalamus, the FTD group as a whole was significantly more asymmetric than controls (0.032 (0.024) versus 0.015 (0.012) ANCOVA, <0.00005). However, consistent with previous findings, the controls had a non-zero asymmetry index. PPA-NOS and SD were the most asymmetric clinical groups, and GRN the most asymmetric among the genetic groups (Figure 2 and
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Discussion
Using an automated and robust segmentation method to segment the thalamus in a large cohort of FTD patients, we demonstrated that thalamic volumes were lower than in controls in all clinical, genetic, and pathological FTD groups except those with FUSopathies, and that FTD-MND, C9orf72, and TDP-43 were the subgroups for in vivo on MRI and as close as possible to the diagnosis. They are likely to be lower therefore than any pathological studies where the disease will be at a more severe stage.
The most significant clinical, genetic and pathological groups overlap in our study, as FTD-MND is usually a TDP-43opathy and is commonly associated with a C9orf72 mutation. Four out of 7 of the FTD-MND cases here had either a single C9orf72 mutation (2 cases) or a dual mutation of C9orf72 with another gene (2 cases).
However it is clear that lower thalamic volumes are not just driven by the C9orf72 status with overlap of values with other mutations and pathologies.
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Previous studies have shown involvement of the thalamus in patients with ALS without FTD (e.g. in C9orf72-ALS: Bede et al., 2013) and it will be useful to study the FTD/MND continuum further in larger cohorts, given the relatively limited size of the FTD-MND group in this study.
Of all the groups, the FUSopathies seems to have the most intact thalamus, consistent with previous imaging studies . However, this is a rare pathological cause of FTD and there were only 3 patients in this group -larger studies will be required to investigate this further.
Clinically, whilst the combined right and left thalamic volume was highest for PPA-NOS and SD, this was driven by the asymmetrical nature of the disease, with much lower volumes of the left compared with the right thalamus (and the highest asymmetry index). The GRN mutation group also showed asymmetry consistent with previous studies showing that this is generally a very asymmetrical disease The thalamus is a key hub in several brain networks and it is therefore not surprising that it is involved in all the different forms of FTD. We only investigated the whole thalamus volume here but each thalamic nucleus has a distinct pattern of cortical and subcortical connectivity. Future studies, including functional and
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structural connectivity MR analyses of the thalamus, will be needed to investigate the different subnuclei and their connections in order to better understand the role of this key structure in each of the different forms of FTD. Furthermore, improved understanding of the role of the thalamus in different cognitive and behavioural functions may allow better stratification clinically of the FTD syndromes (e.g. those that have abnormal pain and temperature processing [Fletcher et al., 2015] ) and therefore clearer correlation with specific subnuclei. Lastly, the findings of this study suggest that thalamic atrophy may be a useful volumetric imaging biomarker in future disease modifying therapy trials as it is easily measured and universal to all FTD subtypes. 
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A C C E P T E D M A N U S C R I P T A C C E P T E D M A N U S C R I P T Table 3 . Asymmetry values and comparisons between the different clinical, genetic and pathological subgroups for the right, left and total thalamic volume.
Analyses are adjusted for age, gender, scanner type and disease duration. 
Mean (SD) p-value
